This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Brunetti, P. Search for Related Content Social Bookmarking                         What's this?

Pioglitazone — current profile

Department of Internal Medicine and Endocrine and Metabolic Studies, University of Perugia, Via E Dal Pozzo, Perugia 06126, Italy, brunetti{at}dimisem.med.unipg.it

Ploglitazone is a thiazolidinedione that specifically reduces insulin resistance in type 2 diabetes. It has been thoroughly investigated in clinical trials and since its market introduction in 1999 has been prescribed to many patients worldwide. In both monotherapy and combination therapy controlled trials, pioglitazone has proved to be an effective anti-hyperglycaemic agent, reducing fasting plasma glucose and displaying dose-dependent, long-term reductions in glycosylated haemoglobin (HbA1C) compared with placebo. Furthermore, in combination studies, insulin resistance and beta-cell function were significantly improved over baseline and placebo, as measured by HOMA. Pioglitazone also significantly reduced the levels of circulating triglycerides and increased high-density lipoprotein cholesterol without affecting total or low-density lipoprotein cholesterol. In all clinical trials, pioglitazone has been well-tolerated. It may be that the effects of pioglitazone on diabetic dyslipidaemia are at least as important as its effects on lowering blood glucose.

Key Words: diabetes • dyslipidaemia • glycaemic control • efficacy • safety • thiazolidinediones.

References

• Eckland DA, Danhof M. Clinical pharmacokinetics of pioglitazone. Exp Clin Endocrinol Diabetes 2000;108(suppl 2):S234-S242.[CrossRef][Web of Science]
• Edwards G., Eckland DJA. Pharmacokinetics of pioglitazone in patients with renal impairment. Diabetologia 1999;42(suppl 1):A230.
• Yamazaki H., Suzuki M., Tane K. et al. In vitro inhibitory effects of troglitazone and its metabolites on drug oxidation activities of human cytochrome P450 enzymes: comparison with pioglitazone and rosiglitazone. Xenobiotica 2000;30:61-70.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Kortboyer JM, Eckland DJA.Pioglitazone has low potential for drug interactions. Diabetologia 1999;42(suppl 1):A228.
• Kipnes MS, Krosnick A., Rendell MS, Egan JW, Mathisen AL, Schneider RL Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycaemic control in patients with Type 2 diabetes mellitus: a randomised, placebo-controlled study. Am J Med 2001;111:10-17.[Web of Science][Medline] [Order article via Infotrieve]
• Hanefeld M., Göke B. Combining pioglitazone with a sulphonylurea or metformin in the management of type 2 diabetes. Exp Clin Endocrinol Diabetes 2000;108(suppl 2):S256-S266.[CrossRef][Web of Science]
• Rosenstock J. Improved insulin sensitivity and beta cell responsivity suggested by HOMA analysis of pioglitazone therapy. Diabetologia 2000;43 (suppl 1):A-192,Abstract 738.
• Mathisen A., Egan J., Schneider R., Pioglitazone 010 Study Group. The effect of combination therapy with pioglitazone and sulfonylurea on the lipid profile in patients with type 2 diabetes. Diabetes 1999;48 (suppl 1): A106 (abstract).[CrossRef]
• Einhorn D., Rendell M., Rosenzweig J. et al. Pioglitazone hydrochloride in combination with metformin in the treatment of patients with type 2 diabetes mellitus: a randomized placebo-controlled study. Clin Ther 2000;22:1395-409.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Aronoff S., Rosenblatt S., Braithwaite S. et al. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. Diabetes Care 2000;23:1605-11.[Abstract/Free Full Text]
• Yu S. Effect of pioglitazone on blood glucose following an oral glucose challenge. Diabetes 2000;49(suppl 1):A352 (abstract).
• Belcher G., Matthews DR Safety and tolerability of pioglitazone. Exp Clin Endocrinol Diabetes 2000;108(suppl 2):S267-S273.[CrossRef][Web of Science]
• Lawrence JM, Reckless JP Pioglitazone. Int J Clin Pract 2000;54:614-8.[Web of Science][Medline] [Order article via Infotrieve]
• Bicklé JF Thiazolidinediones: clinical data and perspectives. Diabetes Metab 2001;27:279-85.[Web of Science][Medline] [Order article via Infotrieve]
• Hanefeld M., Belcher G. Safety profile of pioglitazone. Int J Clin Pract 2001;121(suppl):27-30.
• Scheen AJ Thiazolidinediones and liver toxicity. Diabetes Metab 2001 27(3):305-13.[Web of Science][Medline] [Order article via Infotrieve]
• Nichôls G., Brown J. Congestive heart failure in type 2 diabetes: prevalence, incidence and risk factors. 36th Annual Meeting of the European Association for the Study of Diabetes, 2000: Abstract.
• Kannel W., Hjortland M., Castelli WP Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol 1974;34:29-34.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Schernthaner G. Cardiovascular mortality and morbidity in Type-2 diabetes mellitus. Diabetes Res Clin Pract 1996;31(suppl):S3-S13.[CrossRef][Medline] [Order article via Infotrieve]
• Stamler J., Vaccaro O., Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16:434-44.[Abstract]
• Reaven GM Insulin resistance - how important is it to treat? Exp Clin Endocrinol Diabetes 2000;108(suppl 2):S274-S280.[CrossRef][Web of Science]
• King AB A comparison in a clinical setting of the efficacy and side effects of three thiazolidinediones. Diabetes Care 2000;23:557.[Web of Science][Medline] [Order article via Infotrieve]

The British Journal of Diabetes & Vascular Disease, Vol. 2, No. 1 suppl, S18-S23 (2002)
DOI: 10.1177/14746514020020010501


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Brunetti, P. Search for Related Content Social Bookmarking                         What's this?